HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. today announced that Eurand, Inc., Cephalon, Inc., and Anesta AG have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company’s submission of Abbreviated New Drug Application (“ANDA”) for cyclobenzaprine hydrochloride extended release capsules (15 and 30 mg), generic of Amrix(R), to the Food and Drug Administration. In connection with this ANDA, IMPAX provided notice that its submission includes a Paragraph IV certification stating the Company believes its product does not infringe U.S. Patent No. 7,387,793, or the patent is invalid or unenforceable.
